Table 3.
Distribution and strength of association as odds ratios (OR) with 95% confidence interval (95% CI) of signs and symptoms with detectable SARS-CoV-2 IgG antibodies.
| Serological Test | OR (95% CI) | p-Value | ||
|---|---|---|---|---|
| Negative Ab | Positive Ab | |||
| COVID-19 compatible symptoms | 545 | 377 | 11.3 (8.4; 15.2) | <0.0001 |
| Fever, n (%) | 167 (30.6) | 234 (62) | 3.7 (2.8; 4.8) | <0.0001 |
| Fatigue, n (%) | 341 (62.6) | 314 (83.3) | 3 (2.2; 4.1) | <0.0001 |
| Headache, n (%) | 278 (51) | 214 (56.8) | 1.3 (0.9; 1.6) | 0.09 |
| Myalgia, n (%) | 215 (39.4) | 245 (65) | 2.9 (2.2; 3.7) | <0.0001 |
| Cough, n (%) | 175 (31.1) | 183 (48.5) | 2 (1.5; 2.6) | <0.0001 |
| Dyspnea, n (%) | 70 (12.8) | 124 (32.8) | 3.3 (2.4; 4.6) | <0.0001 |
| Anosmia, n (%) | 47 (8.6) | 218 (57.8) | 14.5 (10.1; 20.8) | <0.0001 |
| Ageusia, n (%) | 59 (10.8) | 212 (56.2) | 10.6 (7.5; 14.8) | <0.0001 |
| Conjunctivitis, n (%) | 73 (13.4) | 42 (11.1) | 0.8 (0.5; 1.2) | 0.4 |
| Rhinitis, n (%) | 162 (29.7) | 117 (31) | 1.1 (0.8; 1.4) | 0.7 |
| Gastrointestinal discomfort, n (%) | 157 (28.8) | 149 (39.5) | 1.6 (1.2; 2.1) | 0.001 |
| Dermatological lesions, n (%) | 18 (3.3) | 30 (8) | 2.5 (1.4; 4.6) | 0.002 |